{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:45:43Z","timestamp":1792478743482,"version":"4.5.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine the effects of second-line anti-tuberculosis (TB) drugs on the composition and functions of intestinal microbiota in patients with rifampicin-resistant TB (RR-TB).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this cross-sectional study, stool samples and relevant clinical information were collected from patients with RR-TB admitted to the Drug-resistant Specialty Department at Hunan Chest Hospital (Hunan Institute For Tuberculosis Control). The composition and functions of intestinal microbiota were analyzed using metagenomic sequencing and bioinformatics methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Altered structural composition of the intestinal microbiota was found when patients from the control, intensive phase treatment, and continuation phase treatment groups were compared (P&amp;lt;0.05). Second-line anti-TB treatment resulted in a decrease in the relative abundance of species, such as\n                      <jats:italic>Prevotella copri<\/jats:italic>\n                      , compared with control treatment. However, the relative abundance of\n                      <jats:italic>Escherichia coli<\/jats:italic>\n                      ,\n                      <jats:italic>Salmonella enterica<\/jats:italic>\n                      , and 11 other conditionally pathogenic species increased significantly in the intensive phase treatment group. Based on differential functional analysis, some metabolism-related functions, such as the biosynthesises of phenylalanine, tyrosine, and tryptophan, were significantly inhibited during second-line anti-TB drug treatment, while other functions, such as phenylalanine metabolism, were significantly promoted during the intensive phase of treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Second-line anti-TB drug treatment caused changes in the structural composition of the intestinal microbiota in patients with RR-TB. In particular, this treatment induced a significant increase in the relative abundance of 11 conditionally pathogenic species, including\n                      <jats:italic>Escherichia coli.<\/jats:italic>\n                      Functional analysis revealed significantly decreased biosynthesises of phenylalanine, tyrosine, and tryptophan and significantly increased phenylalanine metabolism.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2023.1127916","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T11:03:29Z","timestamp":1682679809000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Effects of second-line anti-tuberculosis drugs on the intestinal microbiota of patients with rifampicin-resistant tuberculosis"],"prefix":"10.3389","volume":"13","author":[{"given":"Chunli","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengzhong","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danlin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengshi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,28]]},"reference":[{"key":"B35","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/s41586-019-1276-2","article-title":"Group 3 innate lymphoid cells mediate early protective immunity against tuberculosis","volume":"570","author":"Ardain","year":"2019","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"150","DOI":"10.15912\/j.cnki.gocm.2016.27.122","article-title":"Analysis of the causes affecting the formation of drug-resistant tuberculosis patients and study of countermeasures","volume":"14","author":"Boratibek","year":"2016","journal-title":"J. China Pharm. Guide"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00615-21","article-title":"Gut mycobiota dysbiosis in pulmonary tuberculosis patients undergoing anti-tuberculosis treatment","volume":"9","author":"Cao","year":"2021","journal-title":"Microbiol. spectrum"},{"key":"B22","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1371\/journal.pcbi.0010024","article-title":"Bioinformatics for whole-genome shotgun sequencing of microbial communities","volume":"1","author":"Chen","year":"2005","journal-title":"PloS Comput. Biol."},{"key":"B500","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3760\/cma.j.issn.1001-0939.2019.10.006","article-title":"Expert consensus on the treatment of multidrug- and rifampicin-resistant tuberculosis in China (2019 edition)","volume":"42","year":"2019","journal-title":"Chinese Journal of Tuberculosis and Respiratory Diseases"},{"key":"B19","doi-asserted-by":"publisher","first-page":"859","DOI":"10.3969\/j.issn.1000-6621.2021.09.002","article-title":"Chinese Expert consensus on an all-oral chemotherapy regimen for drug-resistant tuberculosis (2021 edition)","volume":"43","author":"Chou","year":"2021","journal-title":"Chin. J. Prev. Tuberculosis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.immuni.2019.09.014","article-title":"Metabolite-sensing receptor Ffar2 regulates colonic group 3 innate lymphoid cells and gut immunity","volume":"51","author":"Chun","year":"2019","journal-title":"Immunity"},{"key":"B38","doi-asserted-by":"publisher","first-page":"4187","DOI":"10.1038\/s41467-018-06701-4","article-title":"Host-associated niche metabolism controls enteric infection through fine-tuning the regulation of type 3 secretion","volume":"9","author":"Connolly","year":"2018","journal-title":"Nat. Commun."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2016.17","article-title":"Regulation of immune cell function by short-chain fatty acids","volume":"5","author":"Corr\u00eaa-Oliveira","year":"2016","journal-title":"Clin. Trans. Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1136\/gutjnl-2015-309957","article-title":"High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome","volume":"65","author":"De Filippis","year":"2016","journal-title":"Gut"},{"key":"B47","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1111\/1462-2920.13819","article-title":"Inter-individual differences determine the outcome of wheat bran colonization by the human gut microbiome","volume":"19","author":"De Paepe","year":"2017","journal-title":"Environ. Microbiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/s2213-2600(19)30263-2","article-title":"The lancet respiratory medicine commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis","volume":"7","author":"Dheda","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.92973","article-title":"Interleukin-17 limits hypoxia-inducible factor 1\u03b1 and development of hypoxic granulomas during tuberculosis","volume":"2","author":"Domingo-Gonzalez","year":"2017","journal-title":"JCI Insight"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02656","article-title":"The host microbiota contributes to early protection against lung colonization by mycobacterium tuberculosis","volume":"9","author":"Dumas","year":"2018","journal-title":"Front. Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1007\/s00018-019-03370-4","article-title":"The gut microbiome in tuberculosis susceptibility and treatment response: guilty or not guilty","volume":"77","author":"Eribo","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1128\/mSystems.00051-17","article-title":"Insights into butyrate production in a controlled fermentation system via gene predictions","volume":"2","author":"Esquivel-Elizondo","year":"2017","journal-title":"mSystems"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1126\/science.1237439","article-title":"The long-term stability of the human gut microbiota","volume":"341","author":"Faith","year":"2013","journal-title":"Sci. (New York NY)."},{"key":"B31","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/mmi.14058","article-title":"Physiology and central carbon metabolism of the gut bacterium prevotella copri","volume":"109","author":"Franke","year":"2018","journal-title":"Mol. Microbiol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.anaerobe.2014.08.010","article-title":"Butyricicoccus pullicaecorum, a butyrate producer with probiotic potential, is intrinsically tolerant to stomach and small intestine conditions","volume":"30","author":"Geirnaert","year":"2014","journal-title":"Anaerobe"},{"key":"B43","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/1756283x15607414","article-title":"Fecal microbiota transplantation: in perspective","volume":"9","author":"Gupta","year":"2016","journal-title":"Ther. Adv. gastroenterol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/nature18848","article-title":"The microbiota in adaptive immune homeostasis and disease","volume":"535","author":"Honda","year":"2016","journal-title":"Nature"},{"key":"B44","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3969\/j.issn.1008-5971.2019.04.017","article-title":"Clinical efficacy of probiotics in the treatment of pneumonia in the elderly and its effect on inflammatory response and cellular immune function","volume":"27","author":"Hu","year":"2019","journal-title":"J. Pract. Cardiopulmonary Vasc. Disease"},{"key":"B7","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.jinf.2018.08.006","article-title":"Gut microbiota associated with pulmonary tuberculosis and dysbiosis caused by anti-tuberculosis drugs","volume":"78","author":"Hu","year":"2019","journal-title":"J. infect."},{"key":"B24","doi-asserted-by":"publisher","first-page":"D199","DOI":"10.1093\/nar\/gkt1076","article-title":"Data, information, knowledge and principle: back to metabolism in KEGG","volume":"42","author":"Kanehisa","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.3969\/j.issn.1000-6621.2021.11.017","article-title":"Progress of research on the correlation between pulmonary tuberculosis and intestinal flora","volume":"43","author":"Kang","year":"2021","journal-title":"Chin. J. Anti-TB"},{"key":"B17","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41385-019-0147-3","article-title":"Intestinal dysbiosis compromises alveolar macrophage immunity to mycobacterium tuberculosis","volume":"12","author":"Khan","year":"2019","journal-title":"Mucosal Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.cmet.2015.10.001","article-title":"Dietary fiber-induced improvement in glucose metabolism is associated with increased abundance of prevotella","volume":"22","author":"Kovatcheva-Datchary","year":"2015","journal-title":"Cell Metab."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2017.00822","article-title":"Alternation of gut microbiota in patients with pulmonary tuberculosis","volume":"8","author":"Luo","year":"2017","journal-title":"Front. Physiol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/1462-2920.14015","article-title":"Gut microbiome contributes to impairment of immunity in pulmonary tuberculosis patients by alteration of butyrate and propionate producers","volume":"20","author":"Maji","year":"2018","journal-title":"Environ. Microbiol."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h882","article-title":"Multidrug resistant tuberculosis","volume":"350","author":"Millard","year":"2015","journal-title":"BMJ (Clinical Res. ed)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40168-017-0286-2","article-title":"Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy","volume":"5","author":"Namasivayam","year":"2017","journal-title":"Microbiome"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02781-18","article-title":"Gut microbiota metabolite indole propionic acid targets tryptophan biosynthesis in mycobacterium tuberculosis","volume":"10","author":"Negatu","year":"2019","journal-title":"mBio"},{"key":"B6","first-page":"68","volume-title":"Global tuberculosis report 2022","year":"2022"},{"key":"B50","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jinorgbio.2018.01.010","article-title":"Potential drug targets in the mycobacterium tuberculosis cytochrome P450 system","volume":"180","author":"Ortiz de Montellano","year":"2018","journal-title":"J. inorganic Biochem."},{"key":"B18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/nyas.14300","article-title":"Mycobacterium tuberculosis, antimicrobials, immunity, and lung-gut microbiota crosstalk: current updates and emerging advances","volume":"1467","author":"Osei Sekyere","year":"2020","journal-title":"Ann. New York Acad. Sci."},{"key":"B18a","doi-asserted-by":"publisher","first-page":"191","DOI":"10.19871\/j.cnki.xfcrbzz.2018.03.018","article-title":"Classification of tuberculosis (WS196-2017)","volume":"3","year":"2018","journal-title":"Electronic Journal of Emerging Infectious Diseases"},{"key":"B36","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1111\/1574-6976.12075","article-title":"The first 1000 cultured species of the human gastrointestinal microbiota","volume":"38","author":"Rajili\u0107-Stojanovi\u0107","year":"2014","journal-title":"FEMS Microbiol. Rev."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/9351507","article-title":"Proteobacteria: A common factor in human diseases","volume":"2017","author":"Rizzatti","year":"2017","journal-title":"BioMed. Res. Int."},{"key":"B26","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.chom.2017.03.003","article-title":"Anaerobic bacterial fermentation products increase tuberculosis risk in antiretroviral-Drug-Treated HIV patients","volume":"21","author":"Segal","year":"2017","journal-title":"Cell Host Microbe"},{"key":"B27","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41574-019-0205-7","article-title":"SCFAs - the thin microbial metabolic line between good and bad","volume":"15","author":"Serino","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.tibtech.2015.06.011","article-title":"Proteobacteria: microbial signature of dysbiosis in gut microbiota","volume":"33","author":"Shin","year":"2015","journal-title":"Trends Biotechnol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/9781118728291.ch18","article-title":"Diseases produced by clostridium spiroforme","author":"Songer","year":"2016","journal-title":"Clostridial Dis. Animals"},{"key":"B45","doi-asserted-by":"publisher","first-page":"E8141","DOI":"10.1073\/pnas.1617460113","article-title":"Identifying species of symbiont bacteria from the human gut that, alone, can induce intestinal Th17 cells in mice","volume":"113","author":"Tan","year":"2016","journal-title":"Proc. Natl. Acad. Sci. United States America"},{"key":"B21","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1126\/science.1107851","article-title":"Comparative metagenomics of microbial communities","volume":"308","author":"Tringe","year":"2005","journal-title":"Sci. (New York NY)."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.00053","article-title":"Long-term effects of multi-Drug-Resistant tuberculosis treatment on gut microbiota and its health consequences","volume":"11","author":"Wang","year":"2020","journal-title":"Front. Microbiol."},{"key":"B15b","article-title":"WHO consolidated guidelines on tuberculosis: Module 4: Treatment - Drug-resistant tuberculosis treatment [Internet]","year":"2020"},{"key":"B15a","article-title":"WHO consolidated guidelines on tuberculosis: Module 4: Treatment - Drug-susceptible tuberculosis treatment [Internet]","year":"2022"},{"key":"B15","doi-asserted-by":"publisher","first-page":"10767","DOI":"10.1038\/s41598-017-10346-6","article-title":"Antibiotic treatment for tuberculosis induces a profound dysbiosis of the microbiome that persists long after therapy is completed","volume":"7","author":"Wipperman","year":"2017","journal-title":"Sci. Rep."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1128\/mSystems.00587-20","article-title":"Microbiota-derived short-chain fatty acids promote LAMTOR2-mediated immune responses in macrophages","volume":"5","author":"Wu","year":"2020","journal-title":"mSystems"},{"key":"B49","doi-asserted-by":"publisher","first-page":"678","DOI":"10.3969\/j.issn.1006-5725.2022.06.006","article-title":"Effect of conventional antituberculosis chemotherapy on intestinal flora","volume":"38","author":"Zhang","year":"2022","journal-title":"J. Pract. Med."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1127916\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T11:03:39Z","timestamp":1682679819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1127916\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,28]]},"references-count":50,"alternative-id":["10.3389\/fcimb.2023.1127916"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2023.1127916","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,28]]},"article-number":"1127916"}}